←
David Cavalla318 posts
David Cavalla avatar

David Cavalla

@numedicus

A consulting, collaborative organisation focussed on secondary uses for existing drugs, or drug repurposing. Four clinical stage development projects

◷ Joined February 2011▧ 3 Photos and videos
David Cavalla avatar
David Cavalla@numedicus·26 Sep 2022

Do new medicinal products need commercial exclusivity based on patent(s)? Conventional wisdom is 'yes', but for a recent new repurposed product for a rare disease, commercial exclusivity is actually derived mainly from the orphan designation, not patents. drugrepurposing.info/2022/09…

Jonathan Lis avatar
⟳ David Cavalla retweeted
Jonathan Lis@jonlis1·24 Oct 2017

An actual minister said this. Can we read this again? A member of govt admits Brexit's a fantasy they can't deliver. What. Are. We. Doing?

Post attachment
David Cavalla avatar
David Cavalla@numedicus·12 Oct 2017

Not the first time that this old drug has shown promise in AD, but getting the money to follow is difficult!

David Cavalla avatar
David Cavalla@numedicus·20 Sep 2017

OBR figures show #brexit will cost UK £300m a week (AFTER reduction in EU contribs), in ADDITION to £50bn Brexit divorce bill. #stopbrexit

Boris said Brexit would reclaim £350m a week, in reality it will cost us £300m a week. Per year, Vote Leave's figures were out by £33.8bn.